Information

  • Dec 13, 2024

German Economy Will Hardly Grow in 2025, Bundesbank Says

(Bloomberg) -- Germany’s economy will hardly grow in 2025 after shrinking again this year, according to fresh forecasts from Bundesbank.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsHow California Sees the World, and ItselfGross domestic product will fall by 0.2% in 2024, it said Friday — slashing a June prediction for 0.3% growth. Output will exp

  • Dec 12, 2024

Chinese fund touts offshore crypto exposure in Alipay ad amid bitcoin boom

A Chinese fund manager has touted its fund's cryptocurrency exposure in an effort to draw investors amid a historic bitcoin boom, even as Beijing maintains a hostile stance towards the digital assets. A fund advertisement that read "Cryptocurrencies soaring, start investing with 10 yuan" was spotted on Alipay, Chinese fintech giant Ant Group's mobile wallet app, crypto-focused outlet Wu Blockchain reported on Thursday. The fund, a Qualified Domestic Institutional Investor (QDII) fund operated by

  • Dec 12, 2024

Musk says US is demanding he pay penalty over disclosures of his Twitter stock purchases

Elon Musk says the Securities and Exchange Commission wants him to pay a penalty or face charges involving what he disclosed — or failed to disclose — about his purchases of Twitter stock before he bought the social media platform in 2022. In a letter posted by Musk on the platform now called X, his lawyer Alex Spiro tells the outgoing SEC chairman, Gary Gensler, that the commission's demand for a monetary payment is a “misguided scheme” that won't intimidate Musk. The letter also alleges that the commission reopened an investigation this week into Neuralink, Musk's computer-to-human brain interface company.

  • Dec 12, 2024

Why Is Repare Therapeutics Stock Trading Lower On Friday?

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),

  • Dec 12, 2024

Costco's Unique Retail Model And Solid Growth Stand Out In Challenging Market: Analysts

JP Morgan analyst Christopher Horvers reiterated the Overweight rating on Costco Wholesale Corporation (NASDAQ:COST) with a price forecast of $1,090. The analyst suggests that the ongoing global momentum in the business, share gains across various sectors and geographies (including e-commerce growth), and the company’s leverage to a cyclical upswing in big-ticket items (about 20% of the comp) contribute to its strong performance. Additionally, the emerging benefits from advertising revenue make

Popular Post